Project Grant F32AI186291
Award Date
1/10/25
Completion Date
12/31/26
Dollars Obligated
$152K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,000.00 to Case Western Reserve University to conduct research on defining the role of single-cell heterogeneity in bacterial vaginosis (BV). The overarching goal is to identify aspects of diversity that impact BV and provide insights into new strategies for prevention, treatment, and diagnosis. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $494,696 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio (UTHSCSA). The grant will fund research to better understand the translational control mechanisms that allow the fungal pathogen Candida albicans to respond to host environmental stresses and undergo critical morphological changes that enable infection....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $750,815 to the University of Maryland, Baltimore to conduct research on developing novel therapeutic approaches to treat mucormycosis, a deadly invasive fungal infection. The key research objectives are: Examining the role of the host cell hypoxia-response pathway and the ANGPTL4 protein in the pathogenesis of mucormycosis, and exploring the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $170,000 research project by Prokaryotics Incorporated to develop novel antifungal therapeutics. The goal is to perform structural biology studies on the GPI ethanolamine phosphate transferase enzyme MCD4, which is a promising target for new antifungal drug candidates. The research aims to obtain...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 Allergy and Infectious Diseases Research, is funding a $556,843 research initiative at the University of Pittsburgh to investigate the development and regulation of the extrafollicular B cell response. The key objectives are to: Examine the role of B cells in enhancing the extrafollicular response and test the self-renewal capacity of the extrafollicular B cell population....
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) will provide $1,193,457 to the University of Massachusetts Medical School (UMass Medical) from July 2025 to June 2030. The funding will support the production, validation, and provision of immunogenic fungal antigens from major pathogenic fungi to the scientific community. This includes manufacturing crude antigenic preparations,...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 to HMH Hospitals Corporation (doing business as Hackensack University Medical Center) to conduct research on how the fungal pathogen Candida albicans adapts to different host environments, such as the oral and systemic infection niches. The research aims to decipher how the fungal acetylome, regulated by the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $216,264 to the University of Colorado-Denver to characterize the interactions between Group B Streptococcus (GBS) and Candida albicans (CA) within the gastrointestinal and female reproductive tract. The research aims to determine how CA's transcriptional reprogramming of GBS impacts vaginal colonization and disease,...